At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 80 enrolled
Drug / intervention
Sugammadex +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pulmonary Function, Muscle Strength, Time to Extubation and Quality of Recovery in the Post Anesthesia Care Unit After Reversal of Neuromuscular Blockade With Neostigmine or Sugammadex.
In Brief
A Phase 4 clinical trial evaluating Sugammadex and Neostigmine for Incomplete Reversal of Neuromuscular Block. Completed, enrolled 80 participants across 1 site.
Detailed Summary
This study will compare patient recovery measures after reversal of neuromuscular blockade with neostigmine or sugammadex after surgery. Measures include pulmonary function, muscle strength, time to extubation and quality of recovery in the post anesthesia care unit.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartNov 2016
Primary CompletionNov 2017
Study CompletionFeb 2018
TodayJul 2026
First PostedSep 21, 2016
Enrollment StartNov 1, 2016
Primary CompletionNov 9, 2017
Study CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 9.8 years ago
Interventions
Sugammadexdrug
Sugammadex will be given for reversal of neuromuscular blockade.
Neostigminedrug
Neostigmine will be given for reversal of neuromuscular blockade.